Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Carolyn Myers, M.B.A., Ph.D.
Dr. Myers is an accomplished pharmaceutical executive with extensive experience optimizing productivity, creating value and increasing profitability. She has broad general management, business development and commercial expertise in US and global markets, and is adept at developing strategic plans and translating them into actionable objectives that drive performance and growth.
In her most recent position as Vice President, Global Alliance Management & International Brand Business Development at Allergan (NYSE: AGN), Dr. Myers led an Alliance Management team that managed over 150 partners, representing a sizeable portion of Allergan’s promoted and development product portfolio. In her BD role, she led development of ex-US business development strategy, and directed the evaluation and ultimate negotiation of business development opportunities. Earlier, Dr. Myers was Vice President, CNS Marketing at Forest Laboratories (acquired by Allergan in 2015), where she managed the marketing team responsible for CNS brands with $2.5B in annual sales (about 75% of company revenue in 2011). She directed the creation and execution of brand strategies and tactics for marketed brands, for new product launches and for brands in development.
Before joining Allergan, Dr. Myers was President at Dey Laboratories, Mylan’s branded business unit, which had about $580M in sales and more than 300 employees. She managed the entire business unit, including strategic and long-range planning, sales and marketing, clinical development, manufacturing and distribution. During her tenure, she achieved EBITDA growth of 80% in 2009, 28% in 2010 and 26% in 2011. Previously, she was President of Mylan Technologies, a developer and manufacturer of generic and branded transdermal products. She led the prioritization of the drug development pipeline, which ultimately led to FDA approval of three key transdermal products, and directed various BD deals, including licensing the EMSAM® patch to Bristol-Myers Squibb. She also was Vice President, Business Development & Strategic Marketing, working with senior leadership to enhance Mylan’s branded business strategy.
She is a member of Mid Atlantic Bio Angels, a member of AAAS and a board member at the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
http://www.bioensemble.com/about.html
$ Billions ahead
Subsequent to this reporting period, the animal experiment portion of this study has been completed as of the end of January 2018. We have received initial verbal communications that indicate that our drug candidates were non-toxic in terms of behavioral and other observable signs during the study. We are awaiting a final report from the CRO, which is due shortly, and further discussion of next steps in the development of one of these drug candidates as the final clinical candidate for the treatment of shingles.
We have already begun to scale up production of these tested candidates to the larger amounts as estimated to be required for the ensuing Tox Package studies. We have estimated that approximately 500g of the candidate will be needed for such a study, based on discussions with BASi, Inc., IN, the service provider, and Biologics Consulting Group, VA, our regulatory consultants.
The market size for anti-shingles drugs is currently estimated to be in the range of several billions of dollars, even after a new shingles vaccine, Shingrix® (GlaxoSmithKline) has become available, based on a recent report by Dr. Myers of BioEnsemble, LLC, pharma industry consultants, commissioned by the Company.
More specifically, the report estimated that our anti-shingles drug could reach peak annual sales of as much as $2 Billion, depending upon the effectiveness determined in clinical trials, at an assumed 50% market penetration. Based on current pre-clinical data, we believe that there is a very strong probability that our shingles treatment would significantly minimize the shingles pain, accelerate healing, and minimize nerve damage, thereby minimizing the occurrence and severity of post-herpetic neuralgia (PHN). Our pre-clinical drug design efforts have been aimed at developing a treatment for shingles that would have pain reduction effects as well as healing effects on skin. If our anti-VZV drug candidate is as effective in human clinical studies as we see in the skin patch studies and in the cell culture studies, it would be reasonable to anticipate that the substantial reduction in viral load at the site of application would significantly minimize the shingles pain, accelerate healing, and minimize nerve damage, thereby minimizing the occurrence and severity of post-herpetic neuralgia (PHN). If this were borne out in clinical trials, the potential market could be closer to the $2 billion mark. However, initially, we do not plan on performing clinical trials aimed at proving PHN effectiveness, but rather, we plan on performing clinical trials based on VZV related biomarkers and clinical pathology, which we believe would be sufficient for a first indication for approval of the drug for treatment of shingles by the US FDA. We plan on performing observations regarding PHN in these clinical trials so that an informed PHN clinical trial may be performed later.
We have developed strong chemical manufacturing process controls that enable us to produce the backbone polymers with highly restricted and reproducible molecular size range. In fact, we have achieved highly reproducible and scalable processes that have yielded the same polymer molecular sizes across production scales from 10g to 500g. In other words, we are now able to control the length of the backbone polymer to within one monomer unit, irrespective of production scale (at least up to about 1 kg scale).
We believe that this is a remarkable and possibly unmatched achievement in the field of nanomedicines. We plan on scaling up the production of the polymer backbone “nanomicelle” to kilogram scales and do not anticipate any manufacturing constraints at present.
http://www.secinfo.com/d12TC3.j9H7.htm#1stPage
Anil R. Diwan
Overview
Number of Founded Organizations
3
CB Rank (Person)
303,079
Anil R. Diwan
Founder , Chairman & President, Board of Directors
NanoViricides
Location
New York, New York, United States
Gender
Male
LinkedIn
View on LinkedIn
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company...
Read More
Jobs
Number of Current Jobs
1
Number of Past Jobs
2
NanoViricides
Founder , Chairman & President, Board of Directors
Organization Name
Title At Company
Start Date
End Date
TheraCour Pharma, Inc
Founder
—
—
AllExcel, Inc
Founder
https://www.crunchbase.com/person/anil-r-diwan#section-recent-news-and-activity
https://www.crunchbase.com/organization/nanoviricides#section-board-members-and-advisors
Looks good and promising, as per usual!
Diwan knows something!!
Ya think?
The Outsourcing of Pharmaceuticals
Pharmaceutical development costs can reach into the billions, and it takes a long time to bring a new drug to market. Even then, many drugs fail to be clinically effective and subsequently never see the light of day.
Therefore, pharmaceutical companies are not always eager to utilize their onsite resources for drug R&D and choose to outsource.
https://www.news-medical.net/whitepaper/20180212/Market-Highlight-The-Outsourcing-of-Pharmaceuticals.aspx
I have no doubts about NanoViricides ultimate success - none.
I wait in peace and confidence.
All will be revealed.
Investors sentiment decreased to 1.22 in Q3 2017. Its down 1.18, from 2.4 in 2017Q2. It dropped, as 5 investors sold NanoViricides, Inc. shares while 4 reduced holdings. 7 funds opened positions while 4 raised stakes. 3.64 million shares or 0.08% more from 3.63 million shares in 2017Q2 were reported.
Sequoia Ltd Liability Com has invested 0% of its portfolio in NanoViricides, Inc. (NYSEAMERICAN:NNVC). National Bank Of America De has 0% invested in NanoViricides, Inc. (NYSEAMERICAN:NNVC) for 9,816 shares. Wharton Business Lc accumulated 363,513 shares. Northern Corporation invested in 95,158 shares. Pioneer Tru Commercial Bank N A Or holds 100,000 shares. Moreover, Virtu Fincl Limited Liability Company has 0% invested in NanoViricides, Inc. (NYSEAMERICAN:NNVC). Renaissance Limited Liability Com holds 485,000 shares. Deutsche Comml Bank Ag accumulated 0% or 4 shares. Geode Capital Mgmt Limited Liability Co invested 0% of its portfolio in NanoViricides, Inc. (NYSEAMERICAN:NNVC). Moreover, Raymond James Financial Services Advsrs Inc has 0% invested in NanoViricides, Inc. (NYSEAMERICAN:NNVC) for 11,127 shares. Susquehanna Group Incorporated Ltd Liability Partnership owns 33,409 shares. Pittenger And Anderson Incorporated owns 300 shares or 0% of their US portfolio. Wells Fargo And Mn has 0% invested in NanoViricides, Inc. (NYSEAMERICAN:NNVC) for 2,989 shares. Goldman Sachs Grp Incorporated holds 12,883 shares. Quantitative Systematic Strategies Limited Liability Company holds 10,000 shares or 0% of its portfolio.
The stock of Nanoviricides Incorporated (NYSEAMERICAN:NNVC) registered a decrease of 28.27% in short interest. NNVC’s total short interest was 1.03M shares in February as published by FINRA. Its down 28.27% from 1.43 million shares, reported previously. With 131,500 shares average volume, it will take short sellers 8 days to cover their NNVC’s short positions.
The stock increased 4.08% or $0.04 during the last trading session, reaching $1.02. About 184,833 shares traded or 10.66% up from the average. NanoViricides, Inc. (NYSEAMERICAN:NNVC) has declined 13.42% since February 16, 2017 and is downtrending. It has underperformed by 30.12% the S&P500.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company has market cap of $64.60 million. The firm is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus drug candidate that could enable a functional cure for HIV/AIDS. It currently has negative earnings. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; anti-viral eye drops against external eye viral infections; and other research programs against Rabies virus, Ebola, and Marburg viruses.
More notable recent NanoViricides, Inc. (NYSEAMERICAN:NNVC) news were published by: Prnewswire.com which released: “NanoViricides to Present Results On Successful Treatment Of Herpes-Induced …” on October 17, 2017, also Prnewswire.com with their article: “NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles …” published on June 06, 2017, Seekingalpha.com published: “NanoViricides: House Of Cards With -80% Downside, ‘Strong Sell’ Recommendation” on February 11, 2014. More interesting news about NanoViricides, Inc. (NYSEAMERICAN:NNVC) were released by: Seekingalpha.com and their article: “Recent Pharmaceutical Breakthrough But A Faint Blip On NanoViricides’s Flat …” published on June 09, 2017 as well as Prnewswire.com‘s news article titled: “NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal …” with publication date: November 06, 2017.
HIV/AIDS is toast:
NB:
"HIVcide nanoviricide"
Claim 4. Cocktail according to claim 2, characterized in that it is a cocktail capable of eliminating completely the HIV virus in the organism by the synergistic effect of an anti-tumoral pharmaceutical of commercial use (1), such as doxorubicin, or idarubicin, etoptside, chlorambucil, cisplatin, metflam, or bortezomib, or cyclosporine and a inhibitor of P-glycoprotein (2), such as tariquidar, or cetoconazol, verapamil, miodaron, or quinidine, and an antiviral agent of the viricide type (3), which acts directly on the virus, such as N,N-dichloro-2,2-dimethyltaurin (NVC-422) or Nanoviricide (HIVCide), whereby the anti-tumoral and the inhibitor of glycoprotein P will destroy the hiding-place of the HIV virus in the TCD4+ lymphocytes, exposing the virus to the direct action by one of the antiviral compounds the viricide type as mentioned above.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220170360880%22.PGNR.&OS=DN/20170360880&RS=DN/20170360880
http://www.freshpatents.com/-dt20171221ptan20170360880.php
Plastic 2 Oil 2 Pollution = a losing proposition.
Resin makes sense and one other rather important thing....MONEY!
I'm tingling for Tuesday.
Happy day.
Cya at 7.
AM!
Amen.
Nice bump at the close; Tuesday's the day!
Happy Monday.
Tox toast; Oz next!?
Significant comment - "almost no toxicity"!
Keeps the FDA happy to see a wee bit!!!!
Makes them feel important.
Just so long as it moves us toward $100 before the big news makes me justified.
LLPP uses supercritical pressure to do the deed.
And that's a of of pressure!
This is their method:
United States Patent 8,980,143
Loop , et al.
March 17, 2015
Biomass and waste plastics depolymerization machine and methods via supercritical water
Abstract
A method for transforming a selected polymeric material into a plurality of reaction products via supercritical water is disclosed. The method comprises: conveying the selected polymeric material through an extruder, wherein the extruder is configured to continuously convey the selected polymeric material to a supercritical fluid reaction zone; injecting hot compressed water into the supercritical fluid reaction zone, while the extruder is conveying the selected polymeric material into the supercritical fluid reaction zone so as to yield a mixture; retaining the mixture within the reaction zone for a period of time sufficient to yield the plurality of reaction products. The reaction zone may be characterized by a tubular reactor having an adjustably positionable inner tubular spear, wherein the tubular reactor and the inner tubular spear further define an annular space within the reaction zone, and wherein the mixture flows through the annular space and into a reaction products chamber.
Inventors:
Loop; Thomas E. (Seattle, WA), Flynn; James D. (Auburn, WA), Allan; Graham (Kenmore, WA), Van Swearingen; Steven C. (Edmonds, WA), Gaw; Kevin O. (Seattle, WA)
Applicant:
Loop; Thomas E.
Flynn; James D.
Allan; Graham
Van Swearingen; Steven C.
Gaw; Kevin O.
Family ID: 46491272
Appl. No.: 13/297,217
Filed: November 15, 2011
What is claimed is:
1. A method for transforming a selected polymeric material into a plurality of reaction products, the method comprising the steps of: conveying the selected polymeric material through an extruder so as to define a selected polymeric material flowstream, wherein the extruder is configured to continuously convey the selected polymeric material from an upstream inlet to a supercritical fluid reaction zone; injecting hot compressed water into the supercritical fluid reaction zone while the extruder is conveying the selected polymeric material flowstream into the supercritical fluid reaction zone so as to yield a mixture; retaining the mixture within the reaction zone for a period of time sufficient to yield the plurality of reaction products, wherein the reaction zone is defined by a tubular reactor having an inner tubular spear, wherein the tubular reactor and the inner tubular spear further define an annular space within the reaction zone, and wherein the mixture flows through the annular space; and expelling the plurality of reaction products out of the supercritical fluid reaction zone and into a reaction products chamber.
https://goo.gl/mfsMb1
Thank God for NanoViricides!
China confirms first human case of H7N4 bird flu
February 15, 2018
Hong Kong is warning travellers to avoid any contact with poultry in China after a woman was confirmed with the first human case
Hong Kong is warning travellers to avoid any contact with poultry in China after a woman was confirmed with the first human case of the H7N4 strain of bird flu
China has confirmed the first human case of H7N4 bird flu, prompting Hong Kong to issue a health warning for those travelling to the mainland during the busy Lunar New Year holiday.
The strain was identified in a 68-year-old woman from the eastern province of Jiangsu who was admitted to hospital after falling ill on December 25 but had since recovered, according to China's National Health and Family Planning Commission.
"She had contact with live poultry before the onset of symptoms," Hong Kong's Centre for Health Protection said late Wednesday after being informed of the case by Chinese authorities, who said the virus genes were of avian origin.
The world's first human cases of bird flu were reported in Hong Kong in 1997, when six people were killed by the H5N1 strain of the virus. Hundreds more have died worldwide in subsequent outbreaks, especially of highly-virulent strains like H7N9.
The semi-autonomous southern Chinese city is a high-risk area for the spread of communicable diseases because of its high population density and busy regional and international transport links.
"Travellers to the mainland or other affected areas must avoid visiting wet markets, live poultry markets or farms," the Centre for Health Protection warned after the H7N4 strain was reported by China.
Authorities in China and Hong Kong did not provide further details on the H7N4 strain found in the woman, such as its virulence. An outbreak of this type of bird flu hit chickens in New South Wales, Australia, in 1997, according to World Health Organization records.
Hong Kong authorities are already battling a deadly flu outbreak, and were forced to shut down kindergartens and primary schools early for the Chinese New Year break.
Read more at: https://phys.org/news/2018-02-china-human-case-h7n4-bird.html#jCp
Why the large spread?
Something fishy!
Bid Ask
2.52 5.75
All these guys produce is more pollution when the oil they can produce is combusted.
Plastic waste 2 atmospheric pollution.
Where's the sense in that?
There's no loop.
Here's the loop:
Waste plastic 2 resin 2 new plastic 2 waste plastic....repeat.
Do that forever!
Do not turn waste plastic into oil, burn the oil and pollute the atmosphere!!!
Please.
Not yet!
Good things are worth waiting for!
A synthetic cell that produces anti-cancer drugs within a tumor
Next for NanoCides.
There is no end to their talents!
It is exciting times to be involved in nanotech!
The future is ripe with opportunities and I see NanoCides grabbing one huge share.
More blockbuster news for NanoCides
Posted: Feb 12, 2018
Cancer-fighting nanorobots programmed to seek and destroy tumors
(Nanowerk News)
In a major advancement in nanomedicine, Arizona State University (ASU) scientists, in collaboration with researchers from the National Center for Nanoscience and Technology (NCNST), of the Chinese Academy of Sciences, have successfully programmed nanorobots to shrink tumors by cutting off their blood supply.
"We have developed the first fully autonomous, DNA robotic system for a very precise drug design and targeted cancer therapy," said Hao Yan, director of the ASU Biodesign Institute's Center for Molecular Design and Biomimetics and the Milton Glick Professor in the School of Molecular Sciences.
"Moreover, this technology is a strategy that can be used for many types of cancer, since all solid tumor-feeding blood vessels are essentially the same," said Yan
The successful demonstration of the technology, the first-of-its-kind study in mammals utilizing breast cancer, melanoma, ovarian and lung cancer mouse models, was published in the journal Nature Biotechnology ("A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo").
thrombin-loaded DNA nanobot
Thrombin can block tumor blood flow by clotting the blood within the vessels that feed tumor growth, causing a sort of tumor mini-heart attack, and leading to tumor tissue death. (Image: Jason Drees, Arizona State University)
Seek and destroy
Yan is an expert in the field of DNA origami, which in the past two decades, has developed atomic-scale manufacturing to build more and more complex structures.
The bricks to build their structures come from DNA, which can self-fold into all sorts of shapes and sizes ---all at a scale one thousand times smaller than the width of a human hair---in the hopes of one day revolutionizing computing, electronics and medicine.
That one day may be coming a bit faster than anticipated.
Nanomedicine is a new branch of medicine that seeks to combine the promise of nanotechnology to open up entirely new avenues for treatments, such as making minuscule, molecule-sized nanoparticles to diagnose and treat difficult diseases, especially cancer.
Until now, the challenge to advancing nanomedicine has been difficult because scientists wanted to design, build and carefully control nanorobots to actively seek and destroy cancerous tumors---while not harming any healthy cells.
The international team of researchers overcame this problem by using a seemingly simple strategy to very selectively seek and starve out a tumor.
This work was initiated about 5 years ago. The NCNST researchers first wanted to specifically cut-off of tumor blood supply by inducing blood coagulation with high therapeutic efficacy and safety profiles in multiple solid tumors using DNA-based nanocarriers. Prof. Hao Yan's expertise has upgraded the nanomedicine design to be a fully programmable robotic system, able to perform its mission entirely on its own.
"These nanorobots can be programmed to transport molecular payloads and cause on-site tumor blood supply blockages, which can lead to tissue death and shrink the tumor," said Baoquan Ding, a professor at the NCNST, located in Beijing, China.
programming a nanorobot to only attacks a cancer cell
The key to programming a nanorobot that only attacks a cancer cell was to include a special payload on its surface, called a DNA aptamer. The DNA aptamer could specifically target a protein, called nucleolin, that is made in high amounts only on the surface of tumor endothelial cells -- and not found on the surface of healthy cells. (Image: Jason Drees, Arizona State University)
Nanorobots to the rescue
To perform their study, the scientists took advantage of a well-known mouse tumor model, where human cancer cells are injected into a mouse to induce aggressive tumor growth.
Once the tumor was growing, the nanorobots were deployed to come to the rescue.
Each nanorobot is made from a flat, rectangular DNA origami sheet, 90 nanometers by 60 nanometers in size. A key blood-clotting enzyme, called thrombin, is attached to the surface.
Thrombin can block tumor blood flow by clotting the blood within the vessels that feed tumor growth, causing a sort of tumor mini-heart attack, and leading to tumor tissue death.
First, an average of four thrombin molecules was attached to a flat DNA scaffold. Next, the flat sheet was folded in on itself like a sheet of paper into a circle to make a hollow tube.
They were injected with an IV into a mouse, then traveled throughout the bloodstream, homing in on the tumors.
The key to programming a nanorobot that only attacks a cancer cell was to include a special payload on its surface, called a DNA aptamer. The DNA aptamer could specifically target a protein, called nucleolin, that is made in high amounts only on the surface of tumor endothelial cells---and not found on the surface of healthy cells.
Once bound to the tumor blood vessel surface, the nanorobot was programmed, like the notorious Trojan horse, to deliver its unsuspecting drug cargo in the very heart of the tumor, exposing an enzyme called thrombin that is key to blood clotting.
The nanorobots worked fast, congregating in large numbers to quickly surround the tumor just hours after injection.
Safe and sound design
First and foremost, the team showed that the nanorobots were safe and effective in shrinking tumors.
"The nanorobot proved to be safe and immunologically inert for use in normal mice and, also in Bama miniature pigs, showing no detectable changes in normal blood coagulation or cell morphology," said Yuliang Zhao, also a professor at NCNST and lead scientist of the international collaborative team.
Most importantly, there was no evidence of the nanorobots spreading into the brain where it could cause unwanted side effects, such as a stroke.
"The nanorobots are decidedly safe in the normal tissues of mice and large animals," said Guangjun Nie, another professor at the NCNST and a key member of the collaborative team.
The treatment blocked tumor blood supply and generated tumor tissue damage within 24 hours while having no effect on healthy tissues. After attacking tumors, most of the nanorobots were cleared and degraded from the body after 24 hours.
By two days, there was evidence of advanced thrombosis, and 3 days, thrombi in all tumor vessels were observed.
The key is to trigger thrombin only when it is inside tumor blood vessels. Also, in the melanoma mouse model, 3 out of 8 mice receiving the nanorobot therapy showed complete regression of the tumors. The median survival time more than doubled, extending from 20.5 to 45 days.
They also tried their system in a test of a primary mouse lung cancer model, which mimics the human clinical course of lung cancer patients. They showed shrinkage of tumor tissues after a 2-week treatment.
Science of the very small goes big
For Yan, the important study milestone represents the end of the beginning for nanomedicine.
"The thrombin delivery DNA nanorobot constitutes a major advance in the application of DNA nanotechnology for cancer therapy," said Yan. "In a melanoma mouse model, the nanorobot not only affected the primary tumor but also prevented the formation of metastasis, showing promising therapeutic potential."
Yan and his collaborators are now actively pursuing clinical partners to further develop this technology.
"I think we are much closer to real, practical medical applications of the technology," said Yan. "Combinations of different rationally designed nanorobots carrying various agents may help to accomplish the ultimate goal of cancer research: the eradication of solid tumors and vascularized metastases. Furthermore, the current strategy may be developed as a drug delivery platform for the treatment of other diseases by modification of the geometry of the nanostructures, the targeting groups and the loaded cargoes."
Source: Arizona State University
https://www.nanowerk.com/nanotechnology-news/newsid=49388.php
Just waiting for NanoCides to provide it.
Using injectable self-assembled nanomaterials for sustained delivery of drugs
https://www.nanowerk.com/nanotechnology-news/newsid=49389.php
I guess not, the after market is rather flat.
Has that blockbuster news been released yet??
NanoCides developing rotating magnetic nano particles to kill cancer cells by destroying their membranes looks like a natural to me.
ASAP.
Just insert some pole forming materials in their polymer micelle and Bob's your uncle!
Easy peasy!!
The ligand attaches the Cide to the cancer cell and an externally applied rotating magnetic field rotates those magnetic nanoparticles which destroy the cancer membrane and cell.
No problem.
No hurry - no one else is even close!!!!
NanoCides isn't the only one using membrane destruction!
Nanoparticle-Mediated Mechanical Destruction of Cell Membranes: A Coarse-Grained Molecular Dynamics Study
Liuyang Zhang†, Yiping Zhao‡, and Xianqiao Wang*†
† College of Engineering, University of Georgia, Athens, Georgia 30602, United States
‡ Department of Physics and Astronomy, University of Georgia, Athens, Georgia 30602, United States
ACS Appl. Mater. Interfaces, 2017, 9 (32), pp 26665–26673
DOI: 10.1021/acsami.7b05741
Publication Date (Web): July 18, 2017
Copyright © 2017 American Chemical Society
*E-mail: xqwang@uga.edu.
http://www.thno.org/ms/getimage.php?name=thnov07p1735g007.jpg
http://www.thno.org/v07p1735.htm
The linchpin for NanoCides success:
http://www.nanoviricides.com/images/fooling_virus_main.png
Right up NanoCides ballywick - destroy the membrane - destroy the bacteria:
Antibacterial applications of graphene oxides
(Nanowerk News) Bacterial infections have been considered as one of the greatest threats to human health. However, due to the increasing spread of multidrug-resistant bacteria, the current antibiotic reservoir appears to be insufficient, thereby necessitating the exploration of novel antibacterial agents.
Nano-antibacterial agents represent a novel strategy for bacterial killing. Compared with antibiotics, nano-antibacterial agents have the following two advantages: i) broad-spectrum bactericidal effects against Gram-positive and Gram-negative bacteria and ii) long-lasting bactericidal effects on the prevention of bacterial growth due to their extraordinary stability.
Significant differences exist in the antibacterial mechanisms between antibiotics and nano-antibacterial agents. Antibiotics can prevent bacterial growth by inhibiting the synthesis of target biomolecules in bacteria, including cell wall, DNA, and proteins. However, nano-antibacterial agents can kill bacteria through the mechanisms of membrane destruction and oxidative stress response and by the interactions with cytosolic molecules (lipid, proteins, DNA, etc.).
Graphene oxide (GO) has attracted extensive attention in several research fields, especially in antibacterial applications.
A review, which was published as cover article of Science Bulletin ("Antibacterial Applications of Graphene Oxides: Structure-Activity Relationships, Molecular Initiating Events and Biosafety"), primarily discussed about the structure-activity relationships (SARs) involved in GO-induced bacterial killing, the molecular initiating events (MIEs), and the biosafety of antibacterial applications.
The corresponding authors are Ruibin Li from the School for Radiation Medicine & Interdisciplinary Sciences in Soochow University and Lingwen Zeng from Guangzhou Institute of Biomedicine and Health in the Chinese Academy of Sciences. GO possesses a unique two-dimensional (2D) honeycombed hydrophobic plane structure and hydrophilic groups, including carboxylic (-COOH) and hydroxyl (-OH) groups on its edge, which determine its excellent antibacterial activity.
Among these antibacterial mechanisms, this review summarized the interactions between GO and bacterial membrane, especially the significant role of MIEs, including redox reaction with biomolecules, mechanical destruction of membranes, and catalysis of extracellular metabolites.
The review also discussed in detail about the physicochemical effect of GO on the bacterial membrane, such as phospholipid peroxidation, insertion, wrapping and trapping effect, lipid extraction, and free radicals induced by GO.
Furthermore, this review not only discussed about the effect of size, shape, and surface functionality on the antibacterial activity to elaborate the SARs but also summarized the antibacterial nanoproducts that can be used for biomedical, environmental, and food engineering applications.
Emphasis was also made on the biosafety of GO when used in the biomedical field, considering that direct exposure of GO-based antibacterial agents to human cells may induce undesirable hazardous effects. Therefore, we must pay close attention to the leakage and release of GO into blood while using GO-coated biomedical devices.
Finally, the review has put forward the future perspective and mentioned the challenges of using GO as a novel nano-antibacterial agent, such as understanding the interactions occurring at GO-bacteria interfaces, the exploration of GO-based nanocomposites to achieve synergistic antibacterial effects, and the immobilization of GO for antibacterial use.
Source: Science China Press
https://www.nanowerk.com/nanotechnology-news/newsid=49373.php
Is SITO not another shilling delight?
I expect all to be clear by Autumn!
It's only populated in a thin strip just north of the US border!
Everything else is pristine as nature intended.
And Inovio will insure that we all will live long and well enough to enjoy it!!
I got into INO at a $1 and watched it go to a dime.
I like it better now!!
I think it has $100 potential.
Let's be perfectly clear - NanoViricides is not NanoCides.....yet!
Give it time.
NanoCides is NanoViricides + cancercides and bacteriacides as well as viricides......a much bigger company with much bigger income!!
Money talks.
Are you listening!
I love Trump almost as much as Inovio.
He loves his army as I do, otherwise we'd be in deep doo doo and that would not be so nice.
Trump plays both parts at the same time - he can't lose, just blame Obama who has much better hair!
We Canadians like to think we are superior and criticize our southern neighbours frequently and then thank our lucky stars!!!!!
Get on board the Cide show!!
Buy the best!
NNVC presently but that will be changed shortly.
To reflect the future. DeCidedly.
You will be beCide yourself in profits.
DeCide today!!!!!!!
At least Inovio doesn't need a decent haircut!
Trump does, left or right side - take your pick!
A brush cut like the military would get him 7 more years in a heartbeat!